1001 related articles for article (PubMed ID: 19729693)
1. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management.
Guha S; Mookerjee S; Guha P; Sardar P; Deb S; Roy PD; Karmakar R; Mani S; Hema MB; Pyne S; Chakraborti P; Deb PK; Lahiri P; Chaudhuri U
Indian Heart J; 2009; 61(4):348-52. PubMed ID: 20635737
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
4. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
[TBL] [Abstract][Full Text] [Related]
5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Denardo SJ; Davis KE; Tcheng JE
Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
[TBL] [Abstract][Full Text] [Related]
7. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
[TBL] [Abstract][Full Text] [Related]
8. Variability in responsiveness to oral antiplatelet therapy.
Angiolillo DJ
Am J Cardiol; 2009 Feb; 103(3 Suppl):27A-34A. PubMed ID: 19166710
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
[TBL] [Abstract][Full Text] [Related]
10. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
[TBL] [Abstract][Full Text] [Related]
11. Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized study.
Cuisset T; Frere C; Quilici J; Uhry S; Morange PE; Mouret JP; Gaborit B; Bali L; Moro PJ; Lambert M; Bonnet JL
Thromb Res; 2009 May; 124(1):33-6. PubMed ID: 18990434
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
[TBL] [Abstract][Full Text] [Related]
15. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Shenkman B; Matetzky S; Fefer P; Hod H; Einav Y; Lubetsky A; Varon D; Savion N
Thromb Res; 2008; 122(3):336-45. PubMed ID: 18155752
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
17. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
18. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
20. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Collet JP; Montalescot G
Int J Cardiol; 2009 Mar; 133(1):8-17. PubMed ID: 19187982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
